The QuantHealth team covers virtual patient simulation, clinical trial design, and drug development methodology.
Population simulation informs Phase 2 protocol choices, including dose, endpoints, and enrollment.
Read articleBefore enrollment, simulation maps outcome probabilities across candidate doses to support Phase 2 dose selection.
Read articleSimulation can use biomarker enrichment to identify responder subgroups before enrollment, avoiding diluted efficacy signals and inflated sample size requirements.
Read articleAdaptive designs may improve efficiency, but their upfront assumptions need testing; simulation stress-tests them before protocol commitment.
Read articlePK/PD modeling shows that pharmacokinetics and clinical endpoint response may not track linearly, making distributions more informative than means.
Read articleOncology dose-finding must balance narrow tolerability and efficacy windows in heterogeneous populations; simulation addresses both.
Read articleIn rare disease trials, small populations make traditional power calculations unreliable; virtual cohort expansion from natural history data changes what is possible.
Read articleAutoimmune trials contend with heterogeneous responses, long endpoints, and regulatory pressure for disease-area differentiation; simulation addresses all three.
Read articleQuantHealth validates virtual patient models through retrospective analysis of publicly available historical trial data, informing confidence in simulation outputs.
Read articleWith Phase 2 failure rates near 50 percent, simulation targets three known, largely avoidable root causes before the protocol locks.
Read article